Rinvoq

GPTKB entity

Statements (155)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:approves gptkb:ulcerative_colitis
gptkb:2020
gptkb:FDA
gptkb:rheumatoid_arthritis
atopic dermatitis
gptkbp:availability prescription only
gptkbp:bioavailability approximately 85%
gptkbp:brand gptkb:Rinvoq
gptkbp:category gptkb:unknown
gptkb:C
gptkbp:class Janus kinase inhibitor
gptkbp:clinical_trial Phase 3
enhanced quality of life
Rinvoq for atopic dermatitis
Rinvoq for rheumatoid arthritis
Rinvoq for ulcerative colitis
improved skin clearance
reduced itch severity
gptkbp:clinical_use treatment of rheumatoid arthritis
treatment of ulcerative colitis
treatment of atopic dermatitis
moderate to severe rheumatoid arthritis
gptkbp:contraindication active infections
history of thrombosis
hypersensitivity to upadacitinib
gptkbp:developed_by gptkb:Abb_Vie
gptkbp:dissolved soluble in DMSO
slightly soluble in water
gptkbp:dosage_form gptkb:tablet
once daily
15 mg
30 mg
gptkbp:drug_interactions immunosuppressants
live vaccines
CYP3 A4 inducers
CYP3 A4 inhibitors
gptkbp:duration long-term
as prescribed by a healthcare provider
gptkbp:effective_date 2020-08-01
gptkbp:financial_support available
educational resources for patients
available patient assistance programs
gptkbp:formulation extended-release
film-coated tablet
15 mg tablet
30 mg tablet
https://www.w3.org/2000/01/rdf-schema#label Rinvoq
gptkbp:indication moderate to severe rheumatoid arthritis
moderate to severe ulcerative colitis
moderate to severe atopic dermatitis
gptkbp:ingredients gptkb:upadacitinib
gptkbp:invention 2028
2028-12-31
gptkbp:is_monitored_by liver function tests
lab tests
regular follow-ups
complete blood count
symptom assessment
lipid levels
gptkbp:lifespan approximately 6 to 14 hours
gptkbp:manufacturer gptkb:Abb_Vie_Inc.
gptkb:Abb_Vie
gptkbp:marketed_as gptkb:Rinvoq
gptkb:2020
gptkb:2021
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:mechanism_of_action Janus kinase inhibitor
inhibits Janus kinase enzymes
gptkbp:patient_education important
importance of adherence to therapy
monitoring for side effects
do not crush or chew tablets
take with or without food
recognizing signs of infection
regular follow-up appointments required
report any signs of infection immediately
gptkbp:patient_population adults
pediatric patients
adults and children 12 years and older
gptkbp:pharmacokinetics oral bioavailability
metabolized by liver
half-life of 9-14 hours
reduction of inflammatory cytokines
inhibition of JAK1
gptkbp:previous_name gptkb:upadacitinib
gptkbp:price high
varies by insurance coverage
approximately $2,000 per month without insurance
gptkbp:provides_guidance_on ACR guidelines
recommended for moderate to severe cases
included in dermatology treatment guidelines
gptkbp:regulatory_compliance approved for ankylosing spondylitis
approved for atopic dermatitis
approved for psoriatic arthritis
approved for rheumatoid arthritis
gptkbp:related_products gptkb:Xeljanz
gptkb:Olumiant
gptkbp:requires available online
prescription only
available on manufacturer's website
gptkbp:research ongoing
gptkbp:route_of_administration oral
gptkbp:safety_measures thromboembolic events
liver function tests
complete blood count
risk of liver problems
risk of thrombosis
risk of blood clots
risk of serious infections
lipid levels
risk of certain cancers
risk of malignancies
risk of malignancy
gptkbp:side_effect heart attack
fatigue
headache
nausea
stroke
gastrointestinal perforation
infections
blood clots
thrombosis
increased risk of infections
malignancy risk
serious infections
gastrointestinal perforations
elevated liver enzymes
increased liver enzymes
malignancies
gptkbp:storage room temperature
protected from moisture
gptkbp:strength 15 mg
30 mg
gptkbp:structure C17 H20 N6 O2
gptkbp:trade gptkb:Rinvoq
gptkbp:treatment varies by individual
improvement in quality of life
reduce symptoms
improve function
may take weeks to see effects
prevent joint damage
reduction in disease activity
gptkbp:type_of_care once daily dosing
gptkbp:used_for gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
atopic dermatitis
treatment of rheumatoid arthritis
treatment of ulcerative colitis
treatment of atopic dermatitis
gptkbp:bfsParent gptkb:ABBV
gptkbp:bfsLayer 5